HYMPAVZI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HYMPAVZI (HYMPAVZI).
HYMPAVZI (concizumab) is a humanized monoclonal antibody that targets the Kunitz-2 domain of tissue factor pathway inhibitor (TFPI). By blocking TFPI, it enhances the extrinsic coagulation pathway, increasing thrombin generation and promoting hemostasis in patients with hemophilia A or B with inhibitors.
| Metabolism | HYMPAVZI undergoes degradation into small peptides and amino acids via general protein catabolism. No specific metabolic enzymes are involved. |
| Excretion | Primarily excreted unchanged in feces (approximately 90%) via biliary elimination; renal excretion accounts for <5%. |
| Half-life | Terminal elimination half-life is approximately 24-30 hours, supporting once-daily dosing. |
| Protein binding | High protein binding >99%, primarily to albumin and to a lesser extent to α1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is approximately 0.15 L/kg, indicating limited extravascular distribution, consistent with high protein binding and confinement to plasma. |
| Bioavailability | Oral bioavailability is approximately 45-60% with moderate variability; absorption is enhanced when administered with a high-fat meal. |
| Onset of Action | Oral: Onset of clinical effect (reduction in factor VIII or IX inhibitors) observed within 1-2 weeks after initiation of therapy. |
| Duration of Action | Duration of action is approximately 24 hours with once-daily dosing; maintains therapeutic effect for bleed prophylaxis through continuous exposure. |
IV infusion: 2000 mg once weekly for first 8 weeks, then 2000 mg every 4 weeks.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required based on GFR; safety not established in severe renal impairment (eGFR <30 mL/min/1.73 m²). |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Use caution; no specific dose recommendation. Child-Pugh C: Not recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients below 18 years. |
| Geriatric use | No specific dose adjustment; consider age-related renal and hepatic function decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HYMPAVZI (HYMPAVZI).
| Breastfeeding | No data on concizumab presence in human milk, effects on breastfed infant, or milk production. Monoclonal antibodies are large molecules and likely excreted in milk in low amounts. M/P ratio unknown. Clinical significance is unknown. Caution is advised. |
| Teratogenic Risk | HYMPAVZI (concizumab) is a monoclonal antibody. No human pregnancy data exist. Based on mechanism of action (anti-TFPI), there is potential for increased bleeding risk to fetus if antibody crosses placenta. In animal studies, no teratogenic effects were observed at doses up to 150 mg/kg/day in cynomolgus monkeys. However, monoclonal antibodies are known to cross the placenta increasingly after the first trimester. The risk is theoretical and no specific trimester risks are defined. |
■ FDA Black Box Warning
WARNING: THROMBOTIC EVENTS AND HYPERSENSITIVITY REACTIONS. Serious and life-threatening thrombotic events have occurred in patients receiving HYMPAVZI. Monitor for signs and symptoms of thrombosis and promptly discontinue if suspected. Hypersensitivity reactions, including anaphylaxis, have been reported. Discontinue permanently if severe hypersensitivity occurs.
| Serious Effects |
["Known severe hypersensitivity to concizumab or any excipients in the formulation."]
| Precautions | ["Thrombotic events: Monitor for signs and symptoms of thrombosis (e.g., deep vein thrombosis, pulmonary embolism).","Hypersensitivity reactions: Including anaphylaxis; discontinue if severe.","Laboratory monitoring: Not required for dosing adjustments.","Use with anticoagulants: Avoid concomitant use with systemic anticoagulants."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal anti-factor Xa activity and bleeding events. Fetal monitoring: assess fetal growth and well-being via ultrasound; if bleeding risks suspected, consider surveillance for intracranial hemorrhage in fetus/neonate. |
| Fertility Effects | No dedicated fertility studies in humans. In animal studies (monkeys), no effects on male or female fertility were observed at doses up to 150 mg/kg/day. Potential for anti-drug antibodies to affect fertility is theoretical. |